Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that are founded on UCSF professor Kevan Shokat's technology, today announced the completion of a $90 million Series A financing led by the Life Sciences Investing business within Goldman Sachs Asset Management, bringing the total financing to $125 million since Versant Ventures founded the company. New investors participating in the Series A include Foresite Capital, Avidity Partners, Cowen Healthcare Investments, and Section 32.
